<DOC>
	<DOCNO>NCT00755807</DOCNO>
	<brief_summary>This study design primarily assess efficacy safety duloxetine 60-120 mg daily ( QD ) compare placebo reduction pain severity participant central neuropathic pain due Multiple Sclerosis .</brief_summary>
	<brief_title>Duloxetine Multiple Sclerosis Pain</brief_title>
	<detailed_description>Study multicenter , randomize , double-blind , parallel , placebo-controlled , 20-week trial 4 study period . Participants screen successfully ( Study Period I ) randomize 1:1 fashion duloxetine 60 mg QD placebo . Starting Study Period II , participant treat double-blind manner 6 week . Participants complete 6-week , double-blind period opportunity participate 12-week , open-label , flexible-dose portion study ( Study Period III ) . Study Period IV taper phase design reduce occurrence discontinuation adverse event . Participants may enter Study Period IV time Visit 3 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Have central neuropathic pain due multiple sclerosis ( MS ) base disease diagnostic criterion Adult male female Have score 4 great daily 24hour average pain score Females must test negative pregnancy study entry Complete daily diary least 70 % day study Participants may continue prescription nonprescription analgesic pain medication long dose stable 1 month prior study entry , agree maintain stable dose throughout study Disease Diagnostic Criteria : Diagnosis MS least 1 year prior study entry No MS flare change disease treatment 3 month prior study entry Daily pain due MS minimum 3 month prior study entry Are currently clinical trial MS diseasemodifying therapy Have pain clearly differentiated cause MS Any current historical diagnosis mania , bipolar disorder , psychosis , schizoaffective disorder History substance abuse dependence Are pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Central Neuropathic Pain</keyword>
	<keyword>Multiple Sclerosis</keyword>
</DOC>